Therefore, targeting NLRP3 in tumors to inhibit the immunosuppressive function of MDSCs may constitute an investigational strategy for the treatment of melanoma, especially in the environment of immunotherapy-resistant tumors. The gene discussed is NLRP3; the disease is melanoma.